Aqua Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Acticlate (doxycyline hyclate), a tetracycline antibacterial for the treatment of susceptible infections including adjunctive therapy in severe acne.

Acticlate is a new formulation of oral doxycycline. The 150mg strength has been designed with two functional scores and is substantially reduced in tablet size compared to other available scored doxycycline tablets.

RELATED: For Acne Scars, PMMA-Collagen Effective

Acticlate will be available in 75mg and 150mg (dual-scored) strength tablets.

For more information call (610) 644-7000 or visit